<DOC>
	<DOCNO>NCT00623831</DOCNO>
	<brief_summary>This phase 1 , open-label , multiple dose , single-arm study . The mixed bacteria vaccine ( MBV ) administer start dose 250 EU ( 1 µL ) escalate subject dose inducing desire pyrogenic effect , define body temperature 38°C 39.5°C . The primary objective determine safety profile MBV subject malignant tumor express NY-ESO-1 antigen identify dose induce desired pyrogenic effect . Secondary objective evaluate immunological effect tumor response subject follow vaccination .</brief_summary>
	<brief_title>A Phase 1 Study Mixed Bacteria Vaccine ( MBV ) Patients With Tumors Expressing NY-ESO-1 Antigen</brief_title>
	<detailed_description>Subjects Cohort 1 enrol receive MBV subcutaneously start dose 250 EU ( 1 µL ; dose level 1 ) administer twice weekly . In absence dose-limiting toxicity ( DLT ) , MBV dose escalate subject MBV dose elicit desired pyrogenic effect , maximum dose 547,000 EU ( dose level 8 ) . Once desired pyrogenic effect observe , subject receive MBV twice weekly 4 dos pyrogenic dose level . Subjects Cohort 2 enrol receive MBV pyrogenic dose level ( determined 60,800 EU [ dose level 6 ] ) twice weekly 6 week . Vaccinations inject intralesionally possible subcutaneously intralesional injection possible . If fever 39.5°C 40°C observe , subject 's dose reduce dose level 5 ( 20,300 EU [ 81 μL ] ) . Subjects observed clinic 6 hour follow vaccination , vital sign measure hourly . At baseline throughout study , subject assess NY-ESO-1-specific humoral cellular immunity , chemistry , hematology , cytokine analysis ( interleukin [ IL ] -1 , IL-6 , interferon [ IFN ] -γ , tumor necrosis factor [ TNF ] -α ) . Safety monitor continuously throughout study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Histologically confirm metastatic melanoma , head neck cancer , transitional cell carcinoma , sarcoma , gastrointestinal stroma tumor ( GIST ) prostate cancer . 2 . Tumor expression NYESO1 reverse transcriptase polymerase chain reaction ( RTPCR ) analysis , preferably , immunohistochemistry . 3 . Expected survival least 6 month . 4 . Karnofsky performance status ≥ 70 % . 5 . Fully recover surgery . 6 . Declined , intolerated complete standard therapy define follow tumor entity : 1 . Melanoma resistance intolerance dacarbazine . 2 . Sarcoma resistance intolerance anthracyclines one platinumcontaining chemotherapy regimen , indication irradiation . 3 . GIST failure intolerance imatinib sunitinib . 4 . Head neck cancer indication irradiation , resistance intolerance platinumcontaining chemotherapy . 5 . Transitional cell carcinoma resistance intolerance cisplatin combine gemcitabine . 6 . Prostate cancer failure antihormonal treatment resistance intolerance docetaxel . 7 . Ovarian carcinoma failure standard chemotherapy consist platinum agent combine taxane anthracycline . 8 . Esophageal cancer failure standard chemotherapy consist platinum agent . 9 . Breast cancer failure intolerance standard first , second thirdline chemotherapy consist taxane anthracycline . No indication resistance standard antihormonal treatment . No indication resistance human epidermal growth factor receptor ( HER ) 2neu targeted therapy . No indication resistance irradiation and/or surgery . 7 . Within last 2 week prior study day 1 , vital laboratory parameter must within normal range , except follow laboratory parameter , must within range specify : Absolute neutrophil count ( ANC ) : ≥ 1,000/mm3 Platelet count : ≥ 75,000/mm3 Alanine aminotransferase ( ALT ) : ≤ 5 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) : ≤ 5 x ULN Total bilirubin : ≤ 2.5 x ULN Creatinine : ≤ 2 mg/dL 8 . Age ≥ 18 year . 9 . Able willing give write informed consent . 1 . Clinically significant heart disease ( New York Heart Association Class III IV ) . 2 . Other serious illness , e.g. , serious infection require antibiotic bleed disorder . 3 . Subjects serious intercurrent illness require hospitalization . 4 . Known human immunodeficiency virus positivity . 5 . Chemotherapy , radiation therapy immunotherapy within 4 week prior first dose study agent ( 6 week nitrosoureas ) . 6 . Known autoimmune disease ( rheumatoid arthritis , systemic lupus erythematosus ) , condition might interfere evaluation induce immune response . Subjects vitiligo melanomaassociated hypopigmentation exclude . 7 . Chronic use immunosuppressive drug systemic corticosteroid . 8 . Other malignancy within 3 year prior entry study , except treat nonmelanoma skin cancer cervical carcinoma situ . 9 . Mental impairment may compromise ability give inform consent comply requirement study . 10 . Lack availability immunological clinical followup assessment . 11 . Participation clinical trial involve another investigational agent within 4 week prior first dose study agent . 12 . Pregnancy breastfeed . 13 . Women childbearing potential : Refusal inability use effective mean contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>MBV</keyword>
	<keyword>Mixed Bacterial Vaccine</keyword>
	<keyword>NY-ESO-1</keyword>
</DOC>